Comis R L
Department of Medical Science, Fox Chase Cancer Center, Philadelphia, PA.
Semin Oncol. 1994 Oct;21(5 Suppl 12):109-13.
Cisplatin is one of the most important anticancer drugs yet developed. It proved critical in the development of curative programs for testicular cancer and in life-prolonging regimens for such diseases as small cell lung cancer, ovarian cancer, and metastatic bladder cancer. Cisplatin currently remains the recommended agent of choice for treatment of several malignancies and is a major reagent in the design of existing clinical trials. Although its analogue, carboplatin, has a constitutional and nonhematologic toxicity profile clearly superior to that of cisplatin, thrombocytopenia associated with carboplatin remains a problem, particularly since it can only be circumvented by means of cellular support, with or without growth factors. Continued laboratory investigations exploring new hypotheses concerning the pharmacodynamics of platinating agents emphasize the importance of the parent compound as well. Thus, in the short term, cisplatin will continue to be used in the therapy of certain major cancers. Ultimately, however, it will be replaced by compounds that both obviate its toxicity and increase its spectrum of activity.
顺铂是迄今已研发出的最重要的抗癌药物之一。它在睾丸癌治愈方案的开发以及小细胞肺癌、卵巢癌和转移性膀胱癌等疾病的延长生命治疗方案中起着关键作用。顺铂目前仍是治疗多种恶性肿瘤的推荐首选药物，并且是现有临床试验设计中的主要试剂。尽管其类似物卡铂在构成和非血液学毒性方面明显优于顺铂，但与卡铂相关的血小板减少症仍然是一个问题，特别是因为它只能通过细胞支持（有无生长因子）来规避。持续的实验室研究探索关于铂类药物药效学的新假设，这也强调了母体化合物的重要性。因此，短期内，顺铂将继续用于某些主要癌症的治疗。然而，最终它将被既能消除其毒性又能扩大其活性谱的化合物所取代。
